Infants showing high local pulmonary inflammation diagnosted by respiratory distress syndrome usually need the second or more pulmonary surfactant and is easier to developing to Brochopulmonary. Cursurf is used worldwide in infants with respiratory distress syndrome, Budesonide is a glucocorticoid with a high local anti-inflammatory effect.Our hypothesis is Cursurf combined with Budesonide could reduced the need of Cursurf and incidence of Brochopulmonary dysplasia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
300
Experimental: Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation
Department of Pediatrics, Daping Hospital, Research Institute of Surgery, Third Military Medical University
Chongqing, Chongqing Municipality, China
need of pulmonary surfactant
The hypothesis is Cursurf/Budesonide could reduced the need of pulmonary surfactant
Time frame: one month
the incidence of bronchopulmonary dysplasia
the hypothesis is Cursurf and Budesonide could reduced the incidence of bronchopulmonary dysplasia.
Time frame: gestional age 36 weeks or later
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.